Low dose salmeterol/fluticasone propionate combination (SFC) via metered dose inhaler (MDI) improves asthma control and quality of life in patients not well controlled on inhaled steroids (ICS)
T. P. McCarthy, H. M. Edin, K. House, A. K. Vandermeer, C. Scott (Uxbridge, United Kingdom; Research Triangle Park, United States Of America)
Source: Annual Congress 2002 - Asthma - Therapy and management -2
Session: Asthma - Therapy and management -2
Session type: Thematic Poster Session
Number: 407
Disease area: Airway diseases
Abstract Introduction: A randomised, double blind, placebo-controlled study showed SFC - Seretide™; 50 (salmeterol [S] 25mcg/fluticasone propionate [FP] 50mcg) MDI 2 bd, improved quality of life and asthma control in patients not controlled on ICS, compared with the components (S & FP) and placebo (PL) (SAS30003). As salmeterol monotherapy is not recommended in the UK, we evaluated patients with prior ICS use (n=144). Method: Asthma control (probability of remaining in study) was assessed. Asthma Quality of Life Questionnaire (AQLQ), was administered, (mean change from baseline >=0.5 clinically meaningful). Results: SFC improved asthma control (p[lte]0.001) compared with S and PL; and AQLQ scores (p[lte]0.007) compared with baseline and all comparators. Results:
Mean Change from Baseline in Overall and Domain AQLQ Scores SFC FP S PL Overall 1.20 (a,b) 0.56 -0.03 -0.06 Asthma symptoms 1.28 (a,b,c) 0.55 -0.16 -0.22 Emotional function 1.32 (a,b,c) 0.58 -0.10 -0.08 Asthma control (patients withdrawing from study) 3% 9% 37% 41% a) p[lte]0.001 v PL, b) p[lte]0.002 v S, c) p[lte]0.007 v FP, d) p[lte]0.001 v S,PL
Discussion: SFC 25/50 MDI achieved significant, clinically meaningful improvements from baseline in quality of life compared with PL, FP and S and greater asthma control compared with S and PL . With new guidelines recommending addition of long-acting β2 agonists as first choice in patients not controlled on ICS, SFC is an effective treatment option which can improve asthma control and patient quality of life.
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. P. McCarthy, H. M. Edin, K. House, A. K. Vandermeer, C. Scott (Uxbridge, United Kingdom; Research Triangle Park, United States Of America). Low dose salmeterol/fluticasone propionate combination (SFC) via metered dose inhaler (MDI) improves asthma control and quality of life in patients not well controlled on inhaled steroids (ICS). Eur Respir J 2002; 20: Suppl. 38, 407
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
A comparison of the efficacy of salmeterol/fluticasone propionate combination (SF) with beclometasone dipropionate (BDP) delivered via metered dose inhaler (MDI) in patients not well controlled on bronchodilators alone Source: Eur Respir J 2001; 18: Suppl. 33, 53s Year: 2001
Salmeterol/fluticasone 50/100 (SFC) dry powder inhaler (DPI) provides improved control and quality of life in patients symptomatic on inhaled corticosteroids (ICS) Source: Eur Respir J 2002; 20: Suppl. 38, 47s Year: 2002
Salmeterol/fluticasone propionate combination (SFC) versus doubling dose of fluticasone propionate (FP) in children with asthma insufficiently controlled on moderate doses of inhaled corticosteroids Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010
Non-inferior efficacy of hydrofluoroalkane (HFA) salmeterol (SALM) metered dose inhaler (MDI) compared to salmeterol chlorofluorocarbon (CFC) in adolescent & adult patients with persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004
Comparison of ciclesonide (MDI) once daily and fluticasone propionate (Diskus®) twice daily in the treatment of patients with moderate asthma Source: Eur Respir J 2006; 28: Suppl. 50, 666s Year: 2006
QVAR pMDI is more cost-effective than fluticasone propionate (FP) or CFC-beclometasone dipropionate (BDP) PMDI in a real-life asthmatic population receiving an increase in ICS dose Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care Year: 2009
Comparison of the long-term efficacy and safety of ipratropium bromide (IB) delivered by a new soft mist inhaler (SMI) versus conventional metered dose inhaler (MDI) in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 69s Year: 2001
Comparison of HFA salmeterol-fluticasone (SFC) combination when given through breath actuated inhaler (BAI) and pressurised meter dose inhaler (pMDI) in patients with moderate-to-severe asthma Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
COPD exacerbation rates by month in the ETHOS trial with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020
Clinical equivalence of salmeterol/fluticasone propionate combination 50/100mcg b.i.d. delivered via DiskusÔ or CFC-free metered dose Inhaler (MDI) in children with asthma Source: Eur Respir J 2003; 22: Suppl. 45, 311s Year: 2003
Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) inhaled from a new soft mist inhaler (SMI) and from a conventional metered dose inhaler (MDI) in asthma patients Source: Eur Respir J 2001; 18: Suppl. 33, 70s Year: 2001
Improved control and compliance in children is achieved with salmeterol/fluticasone combination (SFC) compared with concurrent long-acting β2 agonists (LABA) + inhaled corticosteroids (ICS) Source: Eur Respir J 2003; 22: Suppl. 45, 312s Year: 2003
Budesonide/formoterol single inhaler therapy (SiT) provides superior asthma control compared with fixed dose (FD) budesonide or budesonide/formoterol in patients with severe persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 509s Year: 2004
Salmeterol/fluticasone propionate in a single inhaler device (SLM/FP) versus theophylline (THEO)+FP in patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 386s Year: 2002
Initiation of treatment with the salmeterol/fluticasone propionate (FP) combination product is better than inhaled steroid alone (FP) in asthmatic patients symptomatic on short-acting bronchodilator alone Source: Eur Respir J 2003; 22: Suppl. 45, 410s Year: 2003
Efficacy of salmeterol/fluticasone propionate (50/100mcg/day) delivered via the Diskus™ and MDI in children with asthma Source: Eur Respir J 2003; 22: Suppl. 45, 311s Year: 2003
Single inhaler therapy (SiT) with budesonide/formoterol (BUD/FM) is effective in asthma control Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005
Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) delivered by a new soft mist inhaler (SMI) or a conventional metered dose inhaler (MDI) in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 70s Year: 2001
Once-daily versus twice-daily administration of mometasone furoate dry powder inhaler (MF-DPI) improves lung function in children with asthma previously maintained on inhaled corticosteroids (ICS) Source: Eur Respir J 2004; 24: Suppl. 48, 164s Year: 2004
Differences in patient perceived side effects (PPSE) of inhaled corticosteroids (ICS) between metered dose inhalers (MDI) and dry powder inhalers (DPI) Source: Eur Respir J 2003; 22: Suppl. 45, 474s Year: 2003